N@N

Market Maker Surveillance Report. MBRX, BLCM, MTNB, TOPS, INNL, IDXG, Losing Stocks With Lowest Price Friction For Thursday, M

March 23, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 5452 companies with "abnormal" market making, 3273 companies with positive Friction Factors and 2518 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Thursday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Moleculin Biotech Inc. (NASDAQ:MBRX), Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM), Matinas BioPharma Holdings Inc. (NYSE:MTNB), TOP Ships Inc. (NASDAQ:TOPS), Innocoll (NASDAQ:INNL), PDI Inc. (NASDAQ:IDXG). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  MBRX    $-0.220   -0.17%    1,425,457    37.25%    1,793,203    46.86%    -367,746     -16,716 
  BLCM    $-1.480   -0.10%    358,016      32.88%    433,839      39.84%    -75,823      -512    
  MTNB    $-0.430   -0.13%    286,604      33.06%    308,482      35.58%    -21,878      -509    
  TOPS    $-0.160   -0.12%    1,874,441    37.06%    1,945,160    38.46%    -70,719      -4,420  
  INNL    $-0.150   -0.13%    376,625      33.03%    549,376      48.18%    -172,751     -11,517 
  IDXG    $-0.460   -0.16%    362,499      33.31%    439,569      40.39%    -77,070      -1,675  

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar losses (Change) and extremely low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows MBRX with a dollar loss Thursday of $-0.22000 and a Friction Factor of -16,716 shares. That means that it only took 16,716 more shares of selling than buying to move MBRX lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

Moleculin Biotech Inc. (NASDAQ:MBRX) - Metabasis Therapeutics, Inc. (Metabasis), incorporated in April 1997, is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for chronic diseases involving pathways in the liver. The Company has four product candidates in clinical trials: Pradefovir, CS-917, MB07133 and MB07803. Pradefovir for the treatment of hepatitis B has completed Phase II clinical trials. CS-917 for the treatment of type 2 diabetes is in Phase II clinical trials. MB07133 for the treatment of primary liver cancer is in a Phase I/II clinical trial. MB07803, also for the treatment of type 2 diabetes, is in a Phase I clinical trial. Metabasis uses its HepDirect technology and other liver-targeting technology in collaboration with Merck & Co. to identify drugs to treat hepatitis C infection. The Company also uses NuMimetic technology in collaboration with Merck to treat metabolic diseases such as type 2 diabetes, hyperlipidemia and non-alcoholic steatohepatitis, by inhibiting cholesterol and lipid production in the liver.

Pradefovir

Pradefovir is an oral product candidate designed using the Company's HepDirect technology. It delivers high concentrations of adefovir to the liver, while limiting the amount of adefovir generated outside of the liver to reduce dose-related toxicities.

CS-917

CS-917, an oral product candidate for type 2 diabetes, inhibits a metabolic pathway in the liver called gluconeogenesis, which is responsible for the excessive production of glucose by patients with type 2 diabetes. The product is being developed in partnership with Daiichi Sankyo Co., Ltd., which has completed a number of Phase I clinical trials of CS-917 in healthy volunteers, as well as Phase I and Phase II clinical trials of CS-917 in type 2 diabetic patients. In February 2006, a Phase IIb clinical trial of CS-917 was initiated by Daiichi Sankyo.

MB07133

MB07133 is an intravenously administered product candidate in a Phase I/II clinical trial designed to evaluate safety and preliminary efficacy in a limited number of patients with primary liver cancer. Using the HepDirect technology, the product targets the active form of araC to the liver while decreasing levels of the active form of the drug in tissues outside of the liver.

MB07803

MB07803 is an oral product candidate for type 2 diabetes that was discovered using Metabasis' NuMimetic technology. Designed to have the same mechanism of action as CS-917, the second-generation drug blocks the gluconeogenesis pathway in the liver by inhibiting FBPase.

MB07811

Metabasis has a clinical development candidate, MB07811, for the treatment of high cholesterol and obesity. MB07811 is designed to act by controlling the expression of certain genes in the liver. The product is undergoing pre-clinical development including scale-up, toxicology (animal studies) and formulations development..

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) - BAILIE COMMUNUCATION.

Matinas BioPharma Holdings Inc. (NYSE:MTNB) - MIDDLE TENN BK COLUM.

TOP Ships Inc. (NASDAQ:TOPS) - Top Ships Inc. provides seaborne transportation services worldwide. It owns and operates medium range tanker vessels that transport crude oil, petroleum products, and bulk liquid chemicals. The company transports petroleum products and crude oil for the oil industry. As of December 31, 2015, it had a fleet of two chartered-in 50,000 deadweight ton (dwt) product/chemical tankers vessels, the M/T Stenaweco Energy and the M/T Stenaweco Evolution; two 39,000 dwt product/chemical tankers vessels, the M/T Eco Fleet and the M/T Eco Revolution; and contracts for three newbuilding vessels. The company was formerly known as Top Tankers Inc. and changed its name to Top Ships Inc. in December 2007. Top Ships Inc. was founded in 2000 and is based in Maroussi, Greece..

Innocoll (NASDAQ:INNL) - .

PDI Inc. (NASDAQ:IDXG) - .

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net

Contributing Sources

---